| Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma. | |
| | |
MedLine Citation:
|
PMID: 8535195 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Because of the aggressive nature and frequent recurrence of malignant lymphomas of the undifferentiated type, we used a multi-drug induction chemotherapy regimen that has met with some success in children with similar type of histopathology followed by intensification and 8 cycles of consolidation chemotherapy in an attempt to prolong the duration of remission and survival in adult patients with this diagnosis. Fifty-one patients (median age 35 years) with undifferentiated malignant lymphoma were collected over a 4 year period (1984-1988) and entered into a phase III protocol done under the auspices of the Eastern Cooperative Oncology Group (ECOG). Six patients who had their diagnosis made at surgery and had resection of their tumor were excluded from analysis of response to therapy. Sixty percent of the patients had Stage IV disease. Sixteen patients had marrow involvement and five had central nervous system (CNS) disease. None of the patients received CNS radiation therapy. The 45 patients evaluated for response showed a response rate of 67% (30/45) and a complete response rate of 40% (18/45). Thirteen responders continue disease-free with a median follow-up of > 40 months and have an estimated 5 year survival of 80%. Only two treatment related deaths were reported for the entire group. Patients with undifferentiated non-Burkitt's lymphoma had a longer survival than those with undifferentiated Burkitt's. We concluded that adult patients with undifferentiated lymphomas could be treated successfully with an aggressive multi-drug chemotherapy regimen, consisting of multiple alternating cycles of non-crossed-resistant chemotherapy. Toxicity with this aggressive prolonged regimen was acceptable. |
| | |
Authors:
|
J J Mazza; J D Hines; J W Andersen; R S Neiman; R Mann; M M Oken; M J O'Connell |
Related Documents
:
|
10861815 - Mantle cell lymphoma. a clinicopathologic study of 68 cases from the nebraska lymphoma ... 18647965 - Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and... 8299075 - Primary gastric cd30 (ki-1)-positive large cell non-hodgkin's lymphomas. a clinicopatho... 9272145 - Chemotherapy: the more, the better in malignant lymphoma? 15754335 - The ivado regimen--a pilot study with ifosfamide, vincristine, actinomycin d, and doxor... 10650785 - Multidrug resistant malignant melanoma with intracranial metastasis responding to immun... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 18 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 1995 Jul |
Date Detail:
|
Created Date: 1996-02-07 Completed Date: 1996-02-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 289-96 Citation Subset: IM |
Affiliation:
|
Department of Hematology/Oncology, Marshfield Clinic, WI 54449, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Burkitt Lymphoma / drug therapy*, mortality Cyclophosphamide / therapeutic use Cytarabine / therapeutic use Dose-Response Relationship, Drug Female Humans Injections, Spinal Lymphoma, Non-Hodgkin / drug therapy*, mortality Male Methotrexate / therapeutic use Prednisone / therapeutic use Remission Induction Survival Rate Vincristine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/COMP protocol; 147-94-4/Cytarabine; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A retrospective analysis of treatment outcome in 106 cases of localized gastric non-Hodgkin lymphoma...
Next Document: MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to thera...